Cortical involvement in four cases of primary lateral sclerosis using [(11)C]-flumazenil PET.

Cortical involvement in four cases of primary lateral sclerosis using [(11)C]-flumazenil PET.

Four PLS patients underwent cerebral [(11)C]-flumazenil PET. They were compared firstly with a group of controls, then later directly with a group of sporadic ALS patients and a familial ALS group homozygous for the 'D90A' SOD1 gene mutation. There was a similar pattern of decreased bindin...

Bibliografske podrobnosti
Main Authors:	Turner, M, Hammers, A, Al-Chalabi, A, Shaw, C, Andersen, P, Brooks, D, Leigh, P
Format:	Journal article
Jezik:	English
Izdano:	2007

Podobne knjige/članki

Cortical localisation of neuropsychological impairment in amyotrophic lateral sclerosis (ALS): An [C-11] Flumazenil PET study
od: Wicks, P, et al.
Izdano: (2005)

Neuronal loss associated with cognitive performance in amyotrophic lateral sclerosis: an (11C)-flumazenil PET study.
od: Wicks, P, et al.
Izdano: (2008)

Distinct cerebral lesions in sporadic and 'D90A' SOD1 ALS: Studies with [11C]flumazenil PET
od: Turner, M, et al.
Izdano: (2005)

Distinct cerebral lesions in sporadic and 'D90A' SOD1 ALS: studies with [11C]flumazenil PET.
od: Turner, M, et al.
Izdano: (2005)

Volumetric cortical loss in sporadic and familial amyotrophic lateral sclerosis.
od: Turner, M, et al.
Izdano: (2007)

[11C]-WAY100635 PET demonstrates marked 5-HT1A receptor changes in sporadic ALS.
od: Turner, M, et al.
Izdano: (2005)

PET imaging of GABAA receptors in pancreatic islets by [11C]flumazenil
od: Faïza Maloum-Rami, et al.
Izdano: (2024-12-01)

Cortical function in progressive lower motor neuron disorders and amyotrophic lateral sclerosis: a comparative PET study.
od: Kew, J, et al.
Izdano: (1994)

Abnormal cortical excitability in sporadic but not homozygous D90A SOD1 ALS.
od: Turner, M, et al.
Izdano: (2005)

Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis.
od: Turner, M, et al.
Izdano: (2002)

Cortical function in amyotrophic lateral sclerosis. A positron emission tomography study.
od: Kew, J, et al.
Izdano: (1993)

Mills' and other isolated upper motor neurone syndromes: in vivo study with 11C-(R)-PK11195 PET.
od: Turner, M, et al.
Izdano: (2005)

Cortical 5-HT1A receptor binding in patients with homozygous D90A SOD1 vs sporadic ALS.
od: Turner, M, et al.
Izdano: (2007)

Analysis of terms used for the diagnosis and classification of amyotrophic lateral sclerosis and motor neuron disease
od: Rutter-Locher, Z, et al.
Izdano: (2016)

Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials.
od: Balendra, R, et al.
Izdano: (2015)

Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials
od: Balendra, R, et al.
Izdano: (2015)

Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study.
od: Turner, M, et al.
Izdano: (2004)

[C-11]-WAY100635 PET: A surrogate marker for MND?
od: Turner, M, et al.
Izdano: (2003)

Ciliary neurotrophic factor genotype does not influence clinical phenotype in amyotrophic lateral sclerosis.
od: Al-Chalabi, A, et al.
Izdano: (2003)

Relation between cognitive dysfunction and pseudobulbar palsy in amyotrophic lateral sclerosis.
od: Abrahams, S, et al.
Izdano: (1997)

A proposed staging system for amyotrophic lateral sclerosis.
od: Roche, J, et al.
Izdano: (2012)

Validation of an Amyotrophic Lateral Sclerosis Staging System Using Clinical Trial Data
od: Jones, A, et al.
Izdano: (2013)

ABNORMALITIES OF RESTING AND ACTIVATED CORTICAL BLOOD-FLOW IN AMYOTROPHIC-LATERAL-SCLEROSIS (ALS) AND PROGRESSIVE MUSCULAR-ATROPHY (PMA)
od: Kew, J, et al.
Izdano: (1993)

REM sleep physiology and selective neuronal vulnerability in amyotrophic lateral sclerosis
od: Turner, M, et al.
Izdano: (2020)

Reversal of a Suspected Paradoxical Reaction to Zopiclone with Flumazenil
od: Zarah Jordahn, et al.
Izdano: (2016-01-01)

Regional thalamic MRI as a marker of widespread cortical pathology and progressive frontotemporal involvement in amyotrophic lateral sclerosis
od: Tu, S, et al.
Izdano: (2018)

Biomarkers in amyotrophic lateral sclerosis.
od: Turner, M, et al.
Izdano: (2009)

Estimating clinical stage of amyotrophic lateral sclerosis from the ALS Functional Rating Scale.
od: Balendra, R, et al.
Izdano: (2014)

Health utility decreases with increasing clinical stage in amyotrophic lateral sclerosis.
od: Jones, A, et al.
Izdano: (2014)

Delayed Flumazenil Injection after Endoscopic Sedation Increases Patient Satisfaction Compared with Immediate Flumazenil Injection
Izdano: (2014-01-01)

Amyotrophic lateral sclerosis in an urban setting: a population based study of inner city London.
od: Johnston, C, et al.
Izdano: (2006)

Young-onset amyotrophic lateral sclerosis: Historical and other observations
od: Turner, M, et al.
Izdano: (2012)

Young-onset amyotrophic lateral sclerosis: historical and other observations.
od: Turner, M, et al.
Izdano: (2012)

Multi-Centre Clinical Trial Data Using the King's Amyotrophic Lateral Sclerosis (ALS) Staging System
od: Balendra, R, et al.
Izdano: (2013)

Geographical clustering of amyotrophic lateral sclerosis in South-East England: a population study.
od: Scott, K, et al.
Izdano: (2009)

Quantifying disease progression in amyotrophic lateral sclerosis.
od: Simon, N, et al.
Izdano: (2014)

Impaired corticomuscular and interhemispheric cortical beta oscillation coupling in amyotrophic lateral sclerosis
od: Proudfoot, M, et al.
Izdano: (2018)

Mutations in the vesicular trafficking protein annexin A11 are associated with amyotrophic lateral sclerosis
od: Smith, B, et al.
Izdano: (2017)

In vivo study of cerebral microglial activation in MND using [C-11]-PK11195 PET
od: Turner, M, et al.
Izdano: (2004)

Evolution of white matter damage in amyotrophic lateral sclerosis
od: Gabel, M, et al.
Izdano: (2020)